Free Qstream educational activity – Send questions right to your computer or mobile device!
This activity has been approved for AMA PRA Category 1 Credits™.
This is a free CME activity.
The AUA recognizes the critical role of the primary care provider in treating patients with urologic conditions. This innovative Qstream educational activity examines the diagnosis and treatment of the overactive bladder conditions most relevant to front-line patient care.
How does Qstream work?
Designed for today's mobile world, the innovative Qstream format sends questions via e-mail to your computer or mobile device. This allows you to study "on the go," on a schedule that's most convenient for you. Participants receive 2 questions every 2 days via email. If a question is answered incorrectly, it will be repeated 1 week later. If a question is answered correctly, it will be repeated 2 weeks later. If a question is answered correctly two times in a row, the question is retired from the course and is no longer repeated. The participant completes the course when all of the questions are retired (answered correctly twice in a row).
Developed and used at Harvard Medical School, this unique study format has been proven to increase retention by 170% and learning efficiency by 38%.
This activity includes a total of 20 questions based on the AUA Guideline on OAB. When all of the questions have been retired, the participant will be emailed a link to complete an evaluation and claim credit.
Commercial Support Acknowledgement
This activity was supported by an educational grant from Astellas Scientific and Medical Affairs, Inc.
December 14, 2012
December 14, 2013
Overactive bladder (OAB), defined as 'urgency, with or without urinary incontinence, usually with frequency and nocturia,' affects 33 million men and women in the United States. Overall, up to 17% of American adults suffer from overactive bladder; yet, only 16% of patients with OAB will receive treatment.
Primary Care Providers – Front Line of Screening and Assessment
Experts recommend primary care as the most appropriate setting for screening, diagnosis and primary treatment of OAB. Although the urologist's crucial role in the health care team must not be discounted, the primary care physician stands at the front line of screening and assessment. In fact, a large percentage of urologic complaints can be successfully diagnosed and managed in the primary care setting, without need for specialist referral. Primary care treatment is often less costly, less time consuming, and less invasive than other settings of treatment. Consequently, patients, physicians, health care providers and health care management systems should make full use of the primary care provider in the assessment and management of overactive bladder (OAB).
New AUA Clinical Practice Guideline on Overactive Bladder (OAB)
To ensure consistent, high quality, evidence-based treatment of patients with OAB, the AUA released a Clinical Practice Guideline on Overactive Bladder (OAB) in May 2012. The Guideline focuses on the diagnosis and treatment of OAB and contains useful tools for providers such as a treatment algorithm. The American Board of Urology in conjunction with the AUA continues to emphasize the importance of AUA Guidelines which serve as the basis for clinical diagnostic and treatment formulation.
Program Purpose and Description
The purpose of this activity is to provide primary care providers with AUA's new clinical practice guideline on overactive bladder to augment their knowledge of screening methods and identification and treatment options for OAB in the convenience of their office or practice. Special emphasis will be placed on enhanced communication with patients in regards to treatment. Content will be delivered via QStream (formerly Spaced Ed), an online, sequential question/answer program. This activity consists entirely of questions and answers. To improve retention, questions will repeat based on the user's answer. There are a total of 20 questions.
After completion of this activity, participants should be able to
Primary Care Providers: Primary Care Physicians, Physician Assistants, Medical Students
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA takes responsibility for the content, quality, and scientific integrity of this CME activity.
American Academy of Family Physicians (AAFP)
This enduring material activity, AUA Guidelines on Overactive Bladder for Primary Care Physicians (QStream), has been reviewed and is acceptable for up to 2.50 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins December 14, 2012. Term of approval is for one year from this date with the option of yearly renewal. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medium or combination of media used
A PC-compatible computer running Windows XP, or a Macintosh computer running OS X 10.1 or later, or a Linux computer capable of running Mozilla Firefox 3.0 or later. Processor speed of 800 MHz (1GHz preferred). A minimum of 128 MB of RAM (more preferred). A modem speed of at least 56k (broadband preferred). Internet browser should be one of the following: Internet Explorer 8.0 or later, Firefox 3.0 or later, Chrome 4.0 or later, or Safari 4.0 or later. Software requirement: Adobe Acrobat Reader 9 or newer.
As a provider accredited by the ACCME, the AUA must ensure balance, independence, objectivity and scientific rigor in all its activities.
All persons in a position to control the content of an educational activity (i.e., activity planners and presenters) provided by the AUA are required to disclose to the provider any relevant financial relationships they have with any commercial interest. The AUA must determine if an individual's commercial relationships may influence the educational content with regard to exposition or conclusion, and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from serving as planners or presenters, but rather to provide the audience with information on which they can make informed judgments about the material presented.
E. Ann Gormley, MD
Professor of Surgery
Dartmouth-Hitchcock Med. Ctr.
Disclosures: National Institute of Health – NIDDK
Kathryn L. Burgio, PhD
Professor of Medicine
University of Alabama at Birmingham
Department of Medicine
Disclosures: Pfizer: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
Toby C. Chai, MD
Professor of Surgery
University of Maryland Urology
Disclosures: Allergan: Consultant or Advisor, Scientific Study or Trial; National Institutes of Health; Taris Biomedical: Other; Ion Channel, Inc.: Consultant or Advisor; New England Research Institute: Scientific Study or Trial
Darryl S. Chutka, MD
Associate Professor of Medicine
Disclosures: Nothing to disclose
Deborah J. Lightner, MD
Professor of Urology
Department of Urology
Disclosures: Nothing to disclose
Elspeth McDougall, MD, FRCSC, MHPE
Associate Dean of Continuing Z& Simulation Medical Education
Director, Minimally Invasive Surgery Education Center
Chair, AUA Office of Education
University of California – Irvine
Disclosures: Ethicon Endo-Surgery: Other; Karl Storz Endoscopy American: Other
Harriette Miles Scarpero, MD
Fellowship Trained in Female and Pelvic Reconstruction
St. Thomas Hospital
Medical Plaza East
Disclosures: Pfizer, Inc.: Scientific Study or Trial; American Medical Systems (AMS): Consultant or Advisor; Allergan: Participant or Lecturer; Warner Chilcott: Meeting Participant or Lecturer
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Evidence Based Content
As a provider of continuing medical education accredited by the ACCME, it is the policy of the AUA to review and certify that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
© 2012 American Urological Association Education and Research, Inc.®